JPY 2603.5
(-0.53%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 29.11 Billion JPY | -8.51% |
2022 | 31.82 Billion JPY | 1863.73% |
2021 | 1.62 Billion JPY | -67.91% |
2020 | 5.04 Billion JPY | 501.84% |
2019 | 839.05 Million JPY | -67.62% |
2018 | 2.59 Billion JPY | 44.47% |
2017 | 1.79 Billion JPY | 23.89% |
2016 | 1.44 Billion JPY | -15.52% |
2015 | 1.71 Billion JPY | 107.46% |
2014 | 826.01 Million JPY | 507.05% |
2013 | 136.07 Million JPY | -40.82% |
2012 | 229.91 Million JPY | 192.55% |
2011 | 78.59 Million JPY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 37.11 Billion JPY | 25.4% |
2024 Q1 | 29.59 Billion JPY | 1.65% |
2023 Q2 | 26.68 Billion JPY | -4.58% |
2023 Q3 | 28.64 Billion JPY | 7.34% |
2023 FY | 29.11 Billion JPY | -8.51% |
2023 Q4 | 29.11 Billion JPY | 1.65% |
2023 Q1 | 27.96 Billion JPY | -12.13% |
2022 Q4 | 31.82 Billion JPY | 18.81% |
2022 FY | 31.82 Billion JPY | 1863.73% |
2022 Q3 | 26.78 Billion JPY | -1.37% |
2022 Q2 | 27.15 Billion JPY | -0.99% |
2022 Q1 | 27.42 Billion JPY | 1592.56% |
2021 Q1 | 2.4 Billion JPY | -52.43% |
2021 Q4 | 1.62 Billion JPY | -48.3% |
2021 Q3 | 3.13 Billion JPY | 48.01% |
2021 FY | 1.62 Billion JPY | -67.91% |
2021 Q2 | 2.11 Billion JPY | -11.83% |
2020 Q3 | 1.62 Billion JPY | -24.58% |
2020 Q4 | 5.04 Billion JPY | 211.44% |
2020 FY | 5.04 Billion JPY | 501.84% |
2020 Q2 | 2.14 Billion JPY | 74.82% |
2020 Q1 | 1.22 Billion JPY | 0.0% |
2019 FY | 839.05 Million JPY | -67.62% |
2019 Q3 | 1.41 Billion JPY | -45.28% |
2019 Q2 | 2.59 Billion JPY | 116.38% |
2019 Q1 | 1.19 Billion JPY | 28.88% |
2018 FY | 2.59 Billion JPY | 44.47% |
2018 Q4 | 929.15 Million JPY | -13.41% |
2018 Q3 | 1.07 Billion JPY | -40.17% |
2018 Q2 | 1.79 Billion JPY | 158.47% |
2018 Q1 | 693.91 Million JPY | 2.56% |
2017 Q3 | 928.77 Million JPY | -35.84% |
2017 Q1 | 592.24 Million JPY | -7.78% |
2017 FY | 1.79 Billion JPY | 23.89% |
2017 Q2 | 1.44 Billion JPY | 144.44% |
2017 Q4 | 676.56 Million JPY | -27.16% |
2016 Q3 | 764.9 Million JPY | -55.36% |
2016 FY | 1.44 Billion JPY | -15.52% |
2016 Q1 | 1.24 Billion JPY | 225.38% |
2016 Q2 | 1.71 Billion JPY | 38.03% |
2016 Q4 | 642.23 Million JPY | -16.04% |
2015 Q2 | 826.01 Million JPY | 648.48% |
2015 FY | 1.71 Billion JPY | 107.46% |
2015 Q4 | 381.54 Million JPY | 135.18% |
2015 Q3 | 162.23 Million JPY | -80.36% |
2015 Q1 | 110.35 Million JPY | 9.81% |
2014 Q3 | 98.02 Million JPY | -27.96% |
2014 FY | 826.01 Million JPY | 507.05% |
2014 Q1 | 138.68 Million JPY | -14.31% |
2014 Q4 | 100.5 Million JPY | 2.53% |
2014 Q2 | 136.07 Million JPY | -1.89% |
2013 Q4 | 161.85 Million JPY | 52.28% |
2013 Q3 | 106.28 Million JPY | -53.77% |
2013 Q2 | 229.91 Million JPY | 0.0% |
2013 FY | 136.07 Million JPY | -40.82% |
2012 FY | 229.91 Million JPY | 192.55% |
2011 FY | 78.59 Million JPY | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
KOHJIN BIO CO LTD | 3.24 Billion JPY | -796.672% |
PRISM BioLab Co.,LTD | 63.41 Million JPY | -45813.641% |
GNI Group Ltd. | 26.34 Billion JPY | -10.526% |
Linical Co., Ltd. | 10.3 Billion JPY | -182.529% |
Trans Genic Inc. | 3.81 Billion JPY | -663.647% |
MEDINET Co., Ltd. | 590.2 Million JPY | -4832.921% |
Soiken Holdings Inc. | 697.02 Million JPY | -4076.95% |
Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | -863.811% |
AnGes, Inc. | 2.78 Billion JPY | -943.759% |
OncoTherapy Science, Inc. | 513.6 Million JPY | -5568.595% |
Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 67.79% |
Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -8141.35% |
NanoCarrier Co., Ltd. | 1.64 Billion JPY | -1664.621% |
Carna Biosciences, Inc. | 472.35 Million JPY | -6063.648% |
CanBas Co., Ltd. | 91.98 Million JPY | -31550.105% |
D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | -2562.229% |
RaQualia Pharma Inc. | 809.83 Million JPY | -3495.112% |
Chiome Bioscience Inc. | 593.73 Million JPY | -4803.618% |
Kidswell Bio Corporation | 4.25 Billion JPY | -584.386% |
Oncolys BioPharma Inc. | 566.5 Million JPY | -5039.329% |
Ribomic Inc. | 155.8 Million JPY | -18585.89% |
SanBio Company Limited | 2.25 Billion JPY | -1191.162% |
Healios K.K. | 11.28 Billion JPY | -157.968% |
BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -11486.904% |
Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -7790.054% |
Delta-Fly Pharma, Inc. | 241.49 Million JPY | -11955.76% |
StemRIM | 187 Million JPY | -15469.144% |
CellSource Co., Ltd. | 677.73 Million JPY | -4195.798% |
FunPep Company Limited | 189.32 Million JPY | -15278.029% |
Kringle Pharma, Inc. | 596.95 Million JPY | -4777.135% |
Stella Pharma Corporation | 1.44 Billion JPY | -1916.77% |
TMS Co., Ltd. | 97.68 Million JPY | -29703.047% |
Noile-Immune Biotech Inc. | 91.49 Million JPY | -31720.993% |
Cuorips Inc. | 200.96 Million JPY | -14387.537% |
K Pharma,Inc. | 209.13 Million JPY | -13821.361% |
Takara Bio Inc. | 11.42 Billion JPY | -154.941% |
ReproCELL Incorporated | 741.03 Million JPY | -3828.886% |
PhoenixBio Co., Ltd. | 917.71 Million JPY | -3072.484% |
StemCell Institute Inc. | 3.85 Billion JPY | -656.125% |
Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | -3104.899% |
CellSeed Inc. | 301.04 Million JPY | -9571.014% |